Persistent lymphopenia after dimethyl fumarate and fingolimod treatment

被引：0
|
作者：
Hernandez, I. [1 ]
Mulero, P. [1 ]
Neri, M. J. [1 ]
Redondo, N. [1 ]
Abad, E. [2 ]
Tellez, N. [1 ]
机构：
[1] Hosp Clin Valladolid, Neurol, Valladolid, Spain
[2] Hosp Clin Valladolid, Pharm, Valladolid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P775
引用
收藏
页码：644 / 645
页数：2
相关论文
共 50 条
  • [41] Comparison of natalizumab vs fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two year experience
    Vollmer, B. L.
    Nair, K. V.
    Sillau, S.
    Corboy, J.
    Vollmer, T.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 856 - 857
  • [42] Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience
    Vollmer, Brandi
    Nair, Kavita
    Sillau, Stefan
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2017, 88
  • [43] Delayed-release Dimethyl Fumarate-associated Lymphopenia: On-treatment and Post-treatment Implications
    Chan, Andrew
    Fox, Robert J.
    Bar-Or, Amit
    Chen, Chongshu
    Fam, Sami
    Gold, Ralf
    Hanna, Jerome
    Mehta, Devanghi
    Phillips, J. Theodore
    Yang, Lili
    Miller, Catherine
    NEUROLOGY, 2019, 92 (15)
  • [44] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
  • [45] Delayed-release dimethyl fumarate-associated lymphopenia: on-treatment and post-treatment implications
    Chan, A.
    Foxe, R. J.
    Bar-Or, A.
    Chen, C.
    Fam, S.
    Gold, R.
    Hannan, J.
    Mehta, D.
    Phillips, J. T.
    Yang, L.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 505 - 505
  • [46] Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate
    Dempsey, John Patrick
    Wu, Lisa
    Balshi, Alexandra
    Jun, Claire
    Baber, Ursela
    Sloane, Jacob A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
  • [47] Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
    Matteo Lucchini
    Luca Prosperini
    Maria Chiara Buscarinu
    Diego Centonze
    Antonella Conte
    Antonio Cortese
    Giorgia Elia
    Roberta Fantozzi
    Elisabetta Ferraro
    Claudio Gasperini
    Antonio Ianniello
    Doriana Landi
    Girolama Alessandra Marfia
    Viviana Nociti
    Carlo Pozzilli
    Marco Salvetti
    Carla Tortorella
    Massimiliano Mirabella
    Journal of Neurology, 2021, 268 : 2238 - 2245
  • [48] Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
    Lucchini, Matteo
    Prosperini, Luca
    Buscarinu, Maria Chiara
    Centonze, Diego
    Conte, Antonella
    Cortese, Antonio
    Elia, Giorgia
    Fantozzi, Roberta
    Ferraro, Elisabetta
    Gasperini, Claudio
    Ianniello, Antonio
    Landi, Doriana
    Marfia, Girolama Alessandra
    Nociti, Viviana
    Pozzilli, Carlo
    Salvetti, Marco
    Tortorella, Carla
    Mirabella, Massimiliano
    JOURNAL OF NEUROLOGY, 2021, 268 (06) : 2238 - 2245
  • [49] Age influences lymphopenia in MS patients treated with dimethyl-fumarate
    Mancinelli, C. R.
    Scarpazza, C.
    Rasia, S.
    De Rossi, N.
    Cordioli, C.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 506 - 507
  • [50] Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia
    Loredana La Mantia
    Valentina Prone
    Maria Raffaella Marazzi
    Cristina Erminio
    Alessandra Protti
    Neurological Sciences, 2014, 35 : 1485 - 1486
12345